{"id":2457,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2014-01-31","marketCap":3774.8,"name":"Ultragenyx Pharmaceutical Inc","phone":"14154838800","outstanding":82.11,"symbol":"RARE","website":"https://www.ultragenyx.com/","industry":"Biotechnology"},"price":45.7535,"year":2023,"month":12,"day":19,"weekday":"Tuesday","title":"Impact of Cybersecurity Threats and Data Breaches on Ultragenyx Pharmaceutical Inc Stock and its Industry Peers","date":"2023-12-19","url":"/posts/2023/12/19/RARE","content":[{"section":"Overview of Impact","text":"Cybersecurity threats and data breaches can cause a decline in Ultragenyx Pharmaceutical Inc stock and its industry peers. Investors may lose confidence in the company's ability to safeguard sensitive data and protect intellectual property, leading to a decrease in stock value. Moreover, breaches can result in regulatory fines, legal actions, and potential loss of customer trust, further impacting the company's financial stability."},{"section":"Financial Consequences","text":"Data breaches can lead to financial losses for Ultragenyx and its industry peers. The costs associated with investigating and remediating the breach, notifying affected individuals, providing identity theft protection services, and potential legal settlements can be substantial. These expenses can directly impact the company's profitability, leading to a decline in stock value."},{"section":"Reputation Damage","text":"Cybersecurity threats and data breaches can severely damage the reputation of Ultragenyx and its industry peers. The disclosure of sensitive patient data or research information can erode trust among stakeholders, including patients, healthcare providers, and business partners. This loss of reputation can impact the company's market share, partnerships, and future growth prospects."},{"section":"Operational Disruption","text":"A significant cybersecurity breach can disrupt the operations of Ultragenyx and its industry peers. Malware infections, ransomware attacks, or system compromises can impact critical systems, including research and development, manufacturing, and supply chain management. The temporary or prolonged disruption in operations can lead to delays in product launches, inventory shortages, and loss of revenue."},{"section":"Cybersecurity Vulnerabilities","text":"Pharmaceutical companies like Ultragenyx are particularly vulnerable to cyber attacks due to various factors. These include the potential value of intellectual property and research data, the interconnectedness of systems within the pharmaceutical industry, reliance on third-party vendors and contractors, and the increasing sophistication of cyber threat actors. Furthermore, the global nature of pharmaceutical operations and the sharing of data across international boundaries present additional challenges in maintaining robust cybersecurity defenses."},{"section":"Regulatory and Compliance Risks","text":"Cybersecurity threats and data breaches can also expose Ultragenyx and its industry peers to regulatory and compliance risks. Pharmaceutical companies handle sensitive patient data subject to strict privacy regulations, such as the Health Insurance Portability and Accountability Act (HIPAA). Failure to adequately protect this data can result in significant regulatory fines and penalties, further impacting the company's financial standing."},{"section":"Investor Confidence","text":"The occurrence of cybersecurity threats and data breaches in the pharmaceutical industry can undermine investor confidence. Investors may become wary of investing in a sector with a high risk of cyber attacks and may divert their funds to more secure industries. This loss of investor confidence can affect the overall stock performance of Ultragenyx Pharmaceutical Inc and its industry peers."},{"section":"Mitigating Measures","text":"Ultragenyx and its industry peers should prioritize cybersecurity measures to mitigate the impact of threats and breaches. Implementing robust security protocols, conducting regular vulnerability assessments, training employees on cybersecurity best practices, and partnering with specialized cybersecurity firms can strengthen defenses against potential attacks. Additionally, establishing incident response plans and regularly testing them can ensure prompt detection and containment of breaches, minimizing any negative consequences."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1702904400,"headline":"Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)","id":124581644,"image":"https://s.yimg.com/ny/api/res/1.2/_pSv43B11Sg7Y9pdae.Osg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00NTQ-/https://media.zenfs.com/en/globenewswire.com/eb1262dcc2c40080f3981abeffb3e27b","symbol":"RARE","publisher":"Yahoo","summary":"For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterolNOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hyperchole","url":"https://finance.yahoo.com/news/ultragenyx-receives-european-commission-decision-130000851.html"},{"category":"company","date":1702891740,"headline":"Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome","id":124594577,"image":"","symbol":"RARE","publisher":"PR Newswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=vjn0q79wne"},{"category":"company","date":1702883400,"headline":"Ultragenyx receives EC decision for Evkeeza expanded indication","id":124594579,"image":"","symbol":"RARE","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3262186100"},{"category":"company","date":1702072651,"headline":"Wells Fargo Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Overweight Recommendation","id":124401106,"image":"","symbol":"RARE","publisher":"Fintel","summary":"","url":"https://fintel.io/news/wells-fargo-initiates-coverage-of-ultragenyx-pharmaceutical-rare-with-overweight-recommendation-979"},{"category":"company","date":1702015440,"headline":"Expert Ratings for Ultragenyx Pharmaceutical","id":124397709,"image":"","symbol":"RARE","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247684881"},{"category":"company","date":1702008600,"headline":"Wells Fargo starts Ultragenyx coverage with overweight rating","id":124414737,"image":"","symbol":"RARE","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3248426888"},{"category":"company","date":1701923640,"headline":"Ultragenyx initiated with an Overweight at Wells Fargo","id":124377037,"image":"","symbol":"RARE","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246657176"},{"category":"company","date":1701920220,"headline":"Ultragenyx initiated with bullish view at Wells Fargo","id":124377038,"image":"","symbol":"RARE","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246557546"}]}